Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of “Buy” by Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received an average recommendation of “Buy” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $6.63.

Several research firms recently commented on TSHA. Canaccord Genuity Group boosted their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Chardan Capital reissued a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, November 14th.

Taysha Gene Therapies Price Performance

Shares of TSHA stock opened at $1.85 on Thursday. The stock’s 50-day moving average is $2.13 and its 200 day moving average is $2.25. Taysha Gene Therapies has a 1-year low of $1.19 and a 1-year high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The company has a market cap of $379.14 million, a P/E ratio of 2.94 and a beta of 0.78.

Hedge Funds Weigh In On Taysha Gene Therapies

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning purchased a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at $28,000. Principal Financial Group Inc. acquired a new stake in Taysha Gene Therapies during the 2nd quarter worth about $48,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after buying an additional 17,446 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at about $85,000. Finally, Scientech Research LLC purchased a new stake in shares of Taysha Gene Therapies in the second quarter worth about $97,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.